Monoclonal Antibodies – Page 2

Merck’s Investigational RSV Antibody, Clesrovimab, Meets Primary Safety and Efficacy Endpoints in Phase 2b/3 Trial for Infant Prevention

9 months ago talkbio0Tagged Clesrovimab, Merck, Monoclonal Antibodies, Phase 2b/3 Trial, Respiratory syncytial virus

Merck, RSV, Clesrovimab, Monoclonal Antibody, Infant Prevention, Respiratory Syncytial Virus, Phase 2b/3 Trial

Marea Therapeutics Secures $190M for Cardiometabolic Medicine Development

10 months ago talkbio0Tagged ANGPTL4 gene, cardiometabolic medicine, Cardiovascular Diseases, clinical-stage program, Marea Therapeutics, metabolic dysfunction, Monoclonal Antibodies, Phase 2 trial, Science of genetics

Marea Therapeutics, cardiometabolic medicine, clinical-stage program, genetics, ANGPTL4, monoclonal antibody, phase 2 trial, metabolic dysfunction, cardiovascular disease.

AstraZeneca’s COVID-19 Antibody Treatment Shows Promising Results in Immunocompromised Individuals

11 months ago talkbio0Tagged Antibodies, AstraZeneca, Clinical Trials, COVID19 (disease), Enhance (action), Immune response, Immunocompromised Host, individuals, Monoclonal Antibodies, Neutralization (Chemistry), Protection, Virus

AstraZeneca, COVID-19, antibody treatment, immunocompromised individuals, enhanced protection, clinical trials, monoclonal antibodies, virus neutralization, immune response.

Eisai and Biogen Overcome Filing Hitch, Initiate FDA Submission for Subcutaneous Leqembi

11 months ago talkbio0Tagged Alzheimer 's disease, Amyloid beta-Peptides, Biogen, Blackfoot language, Clinical Trials, Eisai, Leqembi, Monoclonal Antibodies, rolling, subcutaneous, Submission, United States Food and Drug Administration

Eisai, Biogen, FDA submission, Leqembi, subcutaneous, Alzheimer’s disease, rolling submission, BLA, clinical trials, monoclonal antibody, amyloid beta, neurodegenerative disorder